Network pharmacology reveals that Yanghe Decoction inhibits osteosarcoma progression via ROS-induced mitochondrial dysfunction and enhances cisplatin sensitivity - PubMed
a day ago
- #Network Pharmacology
- #Yanghe Decoction
- #Osteosarcoma
- Yanghe Decoction (YHD) inhibits osteosarcoma (OS) progression via ROS-induced mitochondrial dysfunction.
- YHD enhances cisplatin sensitivity in OS cells, showing synergistic effects in vitro and in vivo.
- Network pharmacology identified 67 active components and 101 OS-related targets of YHD, including AKT1, TP53, MAPK14, and CASP3.
- YHD suppresses the PI3K/AKT pathway and activates p38 MAPK signaling.
- YHD promotes apoptosis in OS cells by elevating intracellular reactive oxygen species levels.